Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488778 | 0.83 | S1PR3 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ANPC1 | |
| SCHEMBL4483530 | 0.76 | THRB (0.53) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL1585188 | 0.74 | PSEN1 (0.48) | NPC1ALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL11907694 | 0.74 | PSEN1 (0.48) | NPC1ALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL32670789 | 0.74 | MAPT (0.56) | CYP1A2CYP2C19RAB9ANPC1ALDH1A1 | |
| SCHEMBL29395986 | 0.74 | MAPT (0.56) | CYP1A2CYP2C19RAB9ANPC1ALDH1A1 | |
| SCHEMBL4493780 | 0.74 | MAPT (0.56) | CYP1A2CYP2C19RAB9ANPC1ALDH1A1 | |
| SCHEMBL15333128 | 0.73 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C19RAB9ANPC1 | |
| SCHEMBL30739855 | 0.73 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C19RAB9ANPC1 | |
| SCHEMBL1585189 | 0.73 | TAAR1 (0.55) | RAB9ANPC1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | CYP1A2 2556/4885CYP3A4 2690/4885CYP2C19 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.